Latest Conference Articles

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

Neoadjuvant Chemo Does Not Impact Surgical Risk in Thoracic Esophageal Cancer

January 15th 2021, 10:30pm

Neoadjuvant chemotherapy regimens were not found to increase the risk for perioperative complications in patients who have potentially resectable advanced thoracic esophageal cancer, according to data from the phase 3 JCOG 1109 trial that were virtually presented at the 2021 Gastrointestinal Cancers Symposium.

Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers

Lenvatinib/Pembrolizumab Deemed Safe and Effective in Select GI Cancers

January 15th 2021, 10:15pm

In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.

Lenvatinib Monotherapy Demonstrates Efficacy in the First Line for HCC

Lenvatinib Monotherapy Demonstrates Efficacy in the First Line for HCC

January 15th 2021, 8:00pm

In a retrospective, real-world analysis of patients with unresectable hepatocellular carcinoma in the United States, investigators observed that lenvatinib alone was effective as first-line treatment.

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

January 15th 2021, 7:45pm

Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.

Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers

Nivolumab Shows QoL Improvement in Esophageal and Gastroesophageal Cancers

January 15th 2021, 7:30pm

Esophageal-specific and general quality of life was improved in patients with esophageal/gastroesophageal cancer who received nivolumab in the Checkmate 577 clinical trial, according to subgroup analysis data presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer

Pembrolizumab/Trastuzumab Regimen Effective in Treating HER2-Positive Advanced Gastric, GEJ Cancer

January 15th 2021, 7:00pm

The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.

Camrelizumab Combo Elicits Encouraging Efficacy in Second-Line Esophageal Squamous Cell Carcinoma

Camrelizumab Combo Elicits Encouraging Efficacy in Second-Line Esophageal Squamous Cell Carcinoma

January 15th 2021, 5:45pm

GI Cancers Symposium

Camrelizumab in combination with apatinib demonstrated encouraging clinical efficacy as a second-line treatment of patients with esophageal squamous cell carcinoma and demonstrated acceptable safety in a single-arm, open-label phase 2 clinical trial.

Pembrolizumab Plus Lanreotide Induces High Response Rates in GEP Neuroendocrine Tumors

Pembrolizumab Plus Lanreotide Induces High Response Rates in GEP Neuroendocrine Tumors

January 15th 2021, 5:15pm

ASCO Gastrointestinal Cancers Symposium

Roughly 40% of patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors treated with pembrolizumab in combination with lanreotide achieved stable disease, according to results from the phase 1b/2 PLANET clinical trial presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium.

Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC

Safety of Pembrolizumab With Capecitabine and Bevacizumab Demonstrated in MSS mCRC

January 15th 2021, 5:00pm

GI Symposium Colorectal Cancer Spotlight

Immunotherapy with pembrolizumab in combination with capecitabine-based chemotherapy and the VEGF inhibitor bevacizumab, appeared tolerable as treatment of patients with microsatellite stable metastatic colorectal cancer, showing a safety profile that was expected with the drug, results from a phase 2 study show.

ctDNA Biomarker for Responses, Outcomes Observed for High-Risk Patients With Early Breast Cancer

ctDNA Biomarker for Responses, Outcomes Observed for High-Risk Patients With Early Breast Cancer

December 15th 2020, 4:15pm

San Antonio Breast Cancer Symposium

Following neoadjuvant chemotherapy with or without pembrolizumab in patients with high-risk early-stage breast cancer, the presence of ctDNA was a biomarker for response and distant recurrence-free survival.